View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 15, 2021

DiaSorin concludes acquisition of Luminex for $1.8bn

DiaSorin gains access to Luminex’s multiplexing technology as well as a portfolio of diagnostics and life science solutions.

Italian diagnostics firm DiaSorin has concluded the acquisition of Luminex in an all-cash transaction for an equity value of nearly $1.8bn or $37 per share.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

In April, DiaSorin entered a definitive merger agreement to buy its US rival Luminex.

With expertise in multiplexing technology,  Luminex currently has approximately 900 clients. It focuses on developing, producing and marketing biological testing technologies as well as products with applications in the diagnostics and life science industries.

DiaSorin noted that Luminex’s technology and life science solutions, which support clinical and pharmaceutical research and development, are in line with its diagnostics business.

With the deal, DiaSorin will be able to access Luminex’s multiplexing technology as well as a portfolio that will boost its current offering and aid in increasing its presence in the US.

The acquisition will also include access to Luminex’s applications in the life science sector, which feature both academic and scientific research.

Furthermore, it will boost DiaSorin’s collaboration with biopharma firms and enable better access to clinical multiplexing assays for value-based care projects in the future.

For Luminex, the deal will aid in expanding its technology and solutions outside the US by leveraging DiaSorin’s broad commercial and geographical reach.

DiaSorin CEO Carlo Rosa said: “Today, we begin a new phase of our growth, that will position DiaSorin as a fully-fledged diagnostic and life science player, that can offer increasingly sophisticated solutions to customers worldwide, also via the integration of the multiplexing technology that Luminex has pioneered globally.

“The future success of the diagnostics and life science sectors will be increasingly determined by the ability to innovate through cutting-edge technologies and solutions.

“This is the reason why we believe that Luminex is the perfect asset to boost our growth and to turn us into an even more competitive global company.”

DiaSorin has a presence in five continents, which includes 45 companies, four branches and ten production sites, as well as nine research and development centres.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU